Health Condition 1: O- Medical and Surgical Health Condition 2: G549- Nerve root and plexus disorder, unspecified
Conditions
Interventions
Intervention1: Dexmeditomidine: Patients will receive 0.375% Ropivacaine with 1mcg/kg ( 0.01ml/kg) Dexmeditomidine in a total 40 ml for Erector Spinae plane blocks, bilaterally The primary clinical ou
Sponsors
Pravara Institute of Medical Sciences
Eligibility
Inclusion criteria
Inclusion criteria: Physical Status : ASA Grade 1-11 Surgeries : Elective one or two level posterior lumbar decompression, discectomies, interbody fusion
Exclusion criteria
Exclusion criteria: Contraindication to regional blocks : coagulopathy & infection at the block site. History of opioid abuse. Physical status – more than ASA11. History of allergy to any trial drugs, such as Local Anaesthetics & NSAIDS. Any other condition that precluded study inclusion Patient Refusal
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| observe & evaluate efficacy & duration of analgesiaTimepoint: The primary clinical outcome will be measured in post operative period at 30 minutes for first 2 hours, then at 2,3,4,6,8,12,16,20 & 24 hours respectively | — |
Secondary
| Measure | Time frame |
|---|---|
| sedation Adverse Events SpO2, respiratory rate & evidence of respiratory distressTimepoint: All the patients will be observed for any side effects or complications in the post-operative period for 24 hours & following complications if occurred were noted & treated | — |
Countries
India
Contacts
Public ContactDr Milind Pol
Pravara Institute of medical Sciences
Outcome results
None listed